Literature DB >> 7666535

Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies.

E Hogervorst1, J de Jong, A van Wijk, M Bakker, M Valk, P Nara, J Goudsmit.   

Abstract

The aim of the study was to investigate the influence of V3 loops from naturally occurring viruses on the neutralization sensitivity of a molecularly cloned virus. A selection of well-defined syncytium-inducing (SI) and non-SI V3 loops of a single human immunodeficiency virus type 1-infected individual (H594) and the V3 regions of two SI laboratory strains were inserted in an infectious molecular clone of human immunodeficiency type 1 LAI. Neutralization was performed with a heterologous serum pool and autologous patient serum, using the virus reduction neutralization assay and peripheral blood lymphocytes as target cells. High sensitivity of the chimeric viruses containing the laboratory strain V3 regions to neutralization by H594 sequential sera as well as the heterologous serum pool was found. A statistically significant correlation between the sensitivities of these viruses was seen. In contrast, insertion of the primary isolate NSI and SI envelope V3 loops significantly reduced the neutralization by autologous serum but not by the heterologous serum pool. No correlation was found between the neutralization of the viruses with laboratory strain-derived V3 regions and the viruses with primary isolate V3 domains. We conclude that heterologous antibodies are able to neutralize infectious molecular clones with V3 loops of both SI and NSI viruses, regardless of whether they originated from laboratory strains or primary isolates. However, serum of patient H594 discriminated between the two types of viruses and showed reduced neutralization of the viruses with the autologous NSI and SI primary isolate V3 loops. These results indicated that the neutralization sensitivity of the viruses depended on the capacity of the V3 region to influence the conformation of the virus envelope. These V3-dependent conformational changes partially explain the neutralization sensitivity of laboratory strains and the relative neutralization resistance of primary isolates.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7666535      PMCID: PMC189533     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  72 in total

1.  HIV-1 genomic RNA diversification following sexual and parenteral virus transmission.

Authors:  T F Wolfs; G Zwart; M Bakker; J Goudsmit
Journal:  Virology       Date:  1992-07       Impact factor: 3.616

2.  Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution.

Authors:  J J De Jong; A De Ronde; W Keulen; M Tersmette; J Goudsmit
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

3.  Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual.

Authors:  A T Profy; P A Salinas; L I Eckler; N M Dunlop; P L Nara; S D Putney
Journal:  J Immunol       Date:  1990-06-15       Impact factor: 5.422

4.  Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1.

Authors:  J P Moore; Y Cao; D D Ho; R A Koup
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

5.  Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures.

Authors:  W A O'Brien; S H Mao; Y Cao; J P Moore
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

6.  Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.

Authors:  D C Bou-Habib; G Roderiquez; T Oravecz; P W Berman; P Lusso; M A Norcross
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

7.  Frequent and early HIV-1MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120 V3 domain.

Authors:  G Zwart; N K Back; C Ramautarsing; M Valk; L van der Hoek; J Goudsmit
Journal:  AIDS Res Hum Retroviruses       Date:  1994-03       Impact factor: 2.205

8.  Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization.

Authors:  M Robert-Guroff; A Louie; M Myagkikh; F Michaels; M P Kieny; M E White-Scharf; B Potts; D Grogg; M S Reitz
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

9.  The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides.

Authors:  T Vogel; R Kurth; S Norley
Journal:  J Immunol       Date:  1994-08-15       Impact factor: 5.422

10.  Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees.

Authors:  P L Nara; L Smit; N Dunlop; W Hatch; M Merges; D Waters; J Kelliher; R C Gallo; P J Fischinger; J Goudsmit
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

View more
  6 in total

1.  Neutralization profiles of sera from human immunodeficiency virus (HIV)-infected individuals: relationship to HIV viral load and CD4 cell count.

Authors:  M Nokta; P Turk; K Loesch; R B Pollard
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

2.  Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo.

Authors:  Y Ye; Z H Si; J P Moore; J Sodroski
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4.

Authors:  R E Means; T Matthews; J A Hoxie; M H Malim; T Kodama; R C Desrosiers
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

4.  Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage.

Authors:  D Cecilia; V N KewalRamani; J O'Leary; B Volsky; P Nyambi; S Burda; S Xu; D R Littman; S Zolla-Pazner
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

5.  Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.

Authors:  Miroslaw K Gorny; Constance Williams; Barbara Volsky; Kathy Revesz; Sandra Cohen; Victoria R Polonis; William J Honnen; Samuel C Kayman; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

6.  Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage.

Authors:  A Trkola; T Ketas; V N Kewalramani; F Endorf; J M Binley; H Katinger; J Robinson; D R Littman; J P Moore
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.